Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
6
×
life sciences
6
×
national blog main
alnylam pharmaceuticals
boston top stories
clinical trials
drugs
boston
new york blog main
new york top stories
onpattro
patisiran
rna interference
akcea therapeutics
fda
inotersen
national top stories
pfizer
san diego blog main
san diego top stories
tafamidis
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
new york
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
andrew fire
anylam pharmaceuticals
biotech
cardiomyopathy
craig mello
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
What
alnylam
6
×
drug
6
×
fda
medicine
pharmaceuticals
rna
rnai
interference
ago
approved
data
medicines
new
ok
second
seek
speedy
afternoon
akcea
alnylam’s
amyloidosis
approval
approves
attr
available
based
battle
cells
cholesterol
cleared
debilitating
disease
ema
employ
europe
evidence
far
follows
gene
genetic
Language
Current search:
alnylam
×
drug
×
photo
×
" life sciences "
×
" boston blog main "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug